Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while YieldMax TSLA Option Income Strategy ETF trades at $27.24. Which is the better fit depends on your goals.
| ALNY | TSLY | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $491.22 | $48.25 |
52-Week Low | $278.09 | $26.16 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
TSLY trades at $27.42, down slightly by 0.04% today, with a bearish technical signal from moving averages and key indicators like ADX. The ETF generates high income through weekly distributions, with recent payouts ranging from $0.28 to $0.52 per share. Support levels are at $26 and $27, while resistance lies near $28 and $29. Recent news highlights consistent dividend announcements from YieldMax, reinforcing its income-focused strategy.
The outlook for TSLY hinges on its ability to sustain high distributions amid market volatility. While the ETF offers attractive yield potential, risks include capped upside from covered call strategies and sensitivity to Tesla's stock performance. Investors should weigh income benefits against volatility and capital erosion risks in a bearish technical environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
